Logo Valence
Populaire
Se connecter
Loading data for ERAS — first visit, this takes a few seconds.

Ajouter à la liste de suivi

Erasca Inc.

NasdaqGS: ERAS · Prix en temps réel · USD
18.10
-0.18 (-0.98%)
À la clôture : Aug 18, 2026, 8:00 PM
18.11
+0.06%
Préouverture: 4:14 AM

Erasca Inc. (ERAS) Stock Price, Analysis & Data

-0.98%

Aucune donnée disponible

Cours acheteur13.27
Capitalisation boursière6.33B
Chiffre d’affaires (ttm)n/a
Résultat net (ttm)-287.22M
Bêta0.65
EPS (ttm)-0.94
Ratio P/E (ttm)n/a
P/E prévisionnel-31.11
P/B (ttm)15.63
P/S (ttm)n/a
Earnings DateNov 11, 2026
Cours vendeur23
Volume1,830,092
Volume moy. (20D)4,923,824
Ouverture18.19
Clôture précédente18.28
Fourchette du jour17.85 - 18.72
Intervalle de 52 semaines1.33 - 24.28
Analysten/a
Objectif de prixn/a
Dividendesn/a
Date ex-dividenden/a

À propos de ERAS

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 ...

[En savoir plus]
Industrie Biotechnology
Secteur Healthcare
Date d’introduction Jul 16, 2021
Employés 103
Bourse NasdaqGS
Symbole boursier ERAS
Site web https://www.erasca.com
Profil complet de l’entreprise

Performance financière

En 2025, le chiffre d’affaires de Erasca s’élevait à 0, soit une hausse de undefined% par rapport aux 0 de l’année précédente. Le bénéfice s’élevait à -124.55M, soit une baisse de -22.95%.

États financiers

Surprise sur les résultats

Erasca a publié ses résultats trimestriels le Aug 11, 2026 :
  • Chiffre d’affaires de $0 est inférieur aux estimations de $0, avec NaN% croissance en glissement annuel.
  • EPS de -0.14 est inférieur aux estimations de -0.03, avec -16.67% Baisse en glissement annuel.

    • Prochaine publication des résultats

    Erasca Inc. devrait publier ses résultats le Nov 11, 2026, pendant les heures de marché.
    Les analystes prévoient un chiffre d’affaires de ... Passer à l’offre supérieure
    news image

    1 mois il y a · Simply Wall St.

    Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns

    Erasca stock has delivered an extremely large 1 year gain, yet its valuation checks lean expensive, so the current price is testing how much optimism investors are willing to embed into the story this...

    news image

    1 mois il y a · Simply Wall St.

    Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?

    Erasca (ERAS) has been in focus after updated preliminary Phase 1 data for ERAS-0015 in RAS-mutant solid tumors, including pancreatic cancer, coincided with a sizeable follow-on equity offering and a ...

    news image

    1 mois il y a · Simply Wall St.

    Erasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancers

    Erasca recently reported updated preliminary Phase 1 data for its oral pan-RAS molecular glue ERAS-0015, showing encouraging responses and a generally well-tolerated safety profile in RAS-mutant solid...

    news image

    1 mois il y a · Insider Monkey

    Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results

    Erasca rallied by 8.94 percent on Tuesday to close at $19.50 apiece, as investor sentiment was boosted by the strong clinical trial results of its treatment candidate for RAS-mutant solid tumors, stre...

    news image

    1 mois il y a · Barrons.com

    Robinhood and 4 More Stocks That Were Just Added to This Firm’s ‘Top Picks’ List

    Robinhood Markets is added as a top stock for July. Micron and Oracle are among Mizuho Securities’ top picks for the month.

    Page 1 de 2